Golimumab Therapy in Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-α) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-α agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
|---|---|
| Enthalten in: |
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi - 67(2016), 2 vom: 23. Feb., Seite 64-73 |
| Sprache: |
Koreanisch |
|---|
| Beteiligte Personen: |
Moon, Won [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
91X1KLU43E |
|---|
| Anmerkungen: |
Date Completed 09.01.2017 Date Revised 09.03.2017 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4166/kjg.2016.67.2.64 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM25777047X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM25777047X | ||
| 003 | DE-627 | ||
| 005 | 20231224183542.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||kor c | ||
| 024 | 7 | |a 10.4166/kjg.2016.67.2.64 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0859.xml |
| 035 | |a (DE-627)NLM25777047X | ||
| 035 | |a (NLM)26907481 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a kor | ||
| 100 | 1 | |a Moon, Won |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Golimumab Therapy in Ulcerative Colitis |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.01.2017 | ||
| 500 | |a Date Revised 09.03.2017 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ulcerative colitis is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation and blood-mixed diarrhea. The main treatment has been 5-aminosalicylic acid, steroid, thiopurine, and anti-tumor necrosis factor alpha (TNF-α) antibodies including infliximab, adalimumab, and golimumab. Golimumab, a new anti-TNF-α agent has been recently approved for patients with moderate to severe ulcerative colitis. Its efficacy and safety has been demonstrated in line with infliximab and adalimumab in preclinical and clinical studies. This review will focus on golimumab therapy in ulcerative colitis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adalimumab | |
| 650 | 4 | |a Golimumab | |
| 650 | 4 | |a Infliximab | |
| 650 | 4 | |a Tumor necrosis factor-alpha | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a golimumab |2 NLM | |
| 650 | 7 | |a 91X1KLU43E |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi |d 2003 |g 67(2016), 2 vom: 23. Feb., Seite 64-73 |w (DE-627)NLM14272808X |x 2233-6869 |7 nnns |
| 773 | 1 | 8 | |g volume:67 |g year:2016 |g number:2 |g day:23 |g month:02 |g pages:64-73 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4166/kjg.2016.67.2.64 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 67 |j 2016 |e 2 |b 23 |c 02 |h 64-73 | ||